Pivotal Moment In EU For Potential New Drugs

Janssen’s Ponesimod Up For Approval Recommendation; Veklury Approval Due For Renewal

Decisions are due on several EU marketing applications at the March meeting of the European Medicines Agency’s drug evaluation committee, the CHMP. Also, a number of companies might be asked to address outstanding issues the CHMP has about products they want to market that are near the final stages of review.  

Multiple Sclerosis
Janssen's multiple sclerosis drug ponesimod is among the new medicines up for an opinion by the EMA • Source: Shutterstock

The European Medicines Agency is this week deciding whether to recommend pan-EU marketing authorization for several new medicines, including ponesimod, Janssen Pharmaceutical’s treatment for relapsing forms of multiple sclerosis (MS) that has just been approved in the US.

Ponesimod, approved by the US Food and Drug Administration under the brand name Ponvory, is a once-daily oral selective sphingosine-1-phosphate...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography